SCHEMBL4145384

SCHEMBL4145384

Cc1cc(F)ccc1C(=O)N1CCCC(c2nc(-c3ccncc3)no2)C1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.73
TSHR P16473 3/20 0.73
LMNA P02545 2/20 0.73
HTT P42858 2/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
MEN1 O00255 2/20 0.72
KMT2A Q03164 2/20 0.72
GRM5 P41594 1/20 0.68
CLPP Q16740 1/20 0.68
NPSR1 Q6W5P4 2/20 0.67
HSD11B1 P28845 4/20 0.66
RAB9A P51151 1/20 0.64
POLB P06746 1/20 0.60
PKM P14618 1/20 0.60
TP53 P04637 1/20 0.58
ALOX15 P16050 1/20 0.58
MAPK1 P28482 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4145380 1.00 ALDH1A1 (0.73) ALDH1A1TSHRLMNAHTTSMN1; SMN2
SCHEMBL4151228 0.94 MEN1 (0.82) ALDH1A1TSHRLMNAHTTSMN1; SMN2
SCHEMBL4151222 0.94 MEN1 (0.82) ALDH1A1TSHRLMNAHTTSMN1; SMN2
SCHEMBL4152488 0.92 HSD11B1 (0.79) ALDH1A1TSHRLMNAHTTSMN1; SMN2
SCHEMBL4152481 0.92 HSD11B1 (0.79) ALDH1A1TSHRLMNAHTTSMN1; SMN2
SCHEMBL193362 0.88 GRM5 (0.88) ALDH1A1TSHRLMNAHTTSMN1; SMN2
SCHEMBL193363 0.88 GRM5 (0.88) ALDH1A1TSHRLMNAHTTSMN1; SMN2
SCHEMBL4143168 0.87 GRM5 (0.71) ALDH1A1TSHRLMNAHTTSMN1; SMN2
SCHEMBL4143160 0.87 GRM5 (0.71) ALDH1A1TSHRLMNAHTTSMN1; SMN2
SCHEMBL4138211 0.86 ALDH1A1 (0.71) ALDH1A1TSHRLMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090197897-A1 Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors ADDEX PHARMA SA (CH) 2009-08-06 US claimed
US-20090197897-A1 Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors ADDEX PHARMA SA (CH) 2009-08-06 US disclosed
EP-1896463-A2 NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2008-03-12 EP disclosed
WO-2006123249-A2 NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197897-A1 Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors GRM5, GRM2, GRM3 ALDH1A1 4047/4885TSHR 560/4885LMNA 4756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.